Načítá se...
Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients
Racivir [RCV; (+/−)-β-2′,3′-dideoxy-5-fluoro-3′-thiacytidine], a 50:50 racemic mixture of the two β nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. RCV was administered once a day orally for 14 days at doses of 200, 400...
Uloženo v:
Hlavní autoři: | , , , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
American Society for Microbiology
2005
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1168662/ https://ncbi.nlm.nih.gov/pubmed/15980356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.7.2828-2833.2005 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|